Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03675022 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis
A Early Phase 1 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
NCT03675022 is a Early Phase 1 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 9 participants.
The verdict
NCT03675022, a Early Phase 1 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Obstructive Sleep Apnea (OSA) is a common disorder with serious consequences that remains underrecognized, with \>80% of OSA patients undiagnosed, and undertreated due to inadequate treatment options. The development of additional treatments for OSA, such as pharmacotherapy, are critically needed. The collaboration between Regeneron and Sanofi are funding this project. Regeneron will be providing the drug and the contract will be with Regeneron. Both companies are involved as it is a collaboration across the companies.
Interventions
- DRUG Dupilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-08-15 |
| Est. Completion | 2022-07-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03675022
The ClinicalTrials.gov registry entry for NCT03675022 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dupilumab is the first listed.
NCT03675022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03675022 about?
NCT03675022 is a clinical study titled "Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis". Obstructive Sleep Apnea (OSA) is a common disorder with serious consequences that remains underrecognized, with \>80% of OSA patients undiagnosed, and undertreated due to inadequate treatment options. The development of additional treatments for OSA, such as pharmacotherapy, are critically needed. ...
What is the current status of trial NCT03675022?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2018-08-15. Estimated completion is 2022-07-01.
What interventions are being tested in trial NCT03675022?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT03675022?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.